Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2023 Aug 4

PMID 37539061

Authors

Alexy Inciarte

Ainoa Ugarte

Maria Martinez-Rebollar

Berta Torres

Emma Fernandez

Leire Berrocal

Montserrat Laguno

Lorena de la Mora

Elisa de Lazzari

Pilar Callau

Ivan Chivite

Ana Gonzalez-Cordon

Estela Solbes

Veronica Rico

Laura Barrero

Jose Luis Blanco

Esteban Martinez

Juan Ambrosioni

Josep Mallolas

Affiliations

Soon will be listed here.

Abstract

Background: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for 28 days.

Methods: This was a prospective, open-label, single-arm trial including individuals with potential HIV-1 exposure within 72 hours. The primary endpoint was noncompletion of PEP at day 28. Secondary endpoints were adverse effects, adherence, and rate of seroconversion. We performed follow-up at day 7, week 4, and week 12.

Results: Between September 2019 and March 2022, the study enrolled 399 individuals. Median age was 30 (interquartile range [IQR], 27-36) years, and 91% (n = 364) were male. The mode of exposure was sex between men in 84% (n = 331) of cases; risk assessment for HIV-1 transmission was considered as "high" in 97% (n = 385) of the participants. Median time from exposure to consultation was 24 (IQR, 13-40) hours. Noncompletion of PEP was 29% (n = 114) (95% confidence interval [CI], 24%-33%) and 20% (n = 72) (95% CI, 16%-25%) per modified intention-to-treat. Main reasons for noncompletion were loss to follow-up (n = 104 [91%]) and intolerance (n = 8 [7%]). Older age was associated with a lower risk of premature discontinuation (OR, 0.94; < .001). One hundred twenty-three (31%) participants reported adverse events, mostly mild and self-limited (82%); discontinuation occurred in 8 cases (2%). Adherence to PEP in the assessed users was 96%. There were no HIV seroconversions.

Conclusions: DOR/3TC/TDF is a well-tolerated option for nonoccupational PEP. NCT04233372.

References

Molina J, Squires K, Sax P, Cahn P, Lombaard J, DeJesus E . Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018; 5(5):e211-e220. DOI: 10.1016/S2352-3018(18)30021-3. View

Sterrantino G, Borghi V, Callegaro A, Bruzzone B, Saladini F, Maggiolo F . Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019; 53(4):515-519. DOI: 10.1016/j.ijantimicag.2019.02.007. View

Leal L, Leon A, Torres B, Inciarte A, Lucero C, Mallolas J . A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016; 71(7):1982-6. DOI: 10.1093/jac/dkw048. View

Soulie C, Santoro M, Storto A, Abdi B, Charpentier C, Armenia D . Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. J Antimicrob Chemother. 2020; 75(4):1026-1030. DOI: 10.1093/jac/dkz553. View

Kuhar D, Henderson D, Struble K, Heneine W, Thomas V, Cheever L . Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34(9):875-92. DOI: 10.1086/672271. View

Diaz-Brito V, Leon A, Knobel H, Peraire J, Domingo P, Clotet B . Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2012; 17(2):337-46. DOI: 10.3851/IMP1955. View

Alexander T . Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clin Vaccine Immunol. 2016; 23(4):249-53. PMC: 4820517. DOI: 10.1128/CVI.00053-16. View

Orkin C, Squires K, Molina J, Sax P, Wong W, Sussmann O . Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2018; 68(4):535-544. PMC: 6355823. DOI: 10.1093/cid/ciy540. View

Sperling R, Shapiro D, Coombs R, Todd J, Herman S, McSherry G . Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996; 335(22):1621-9. DOI: 10.1056/NEJM199611283352201. View

10.

Foster R, McAllister J, Read T, Pierce A, Richardson R, McNulty A . Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. Clin Infect Dis. 2015; 61(8):1336-41. DOI: 10.1093/cid/civ511. View

11.

Black R . Animal studies of prophylaxis. Am J Med. 1997; 102(5B):39-44. DOI: 10.1016/s0002-9343(97)00059-4. View

12.

Burty C, Prazuck T, Truchetet F, Christian B, Penalba C, Salmon-Ceron D . Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV. AIDS Patient Care STDS. 2010; 24(1):1-3. DOI: 10.1089/apc.2009.0263. View

13.

Shaffer N, Chuachoowong R, Mock P, Bhadrakom C, Siriwasin W, Young N . Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999; 353(9155):773-80. DOI: 10.1016/s0140-6736(98)10411-7. View

14.

Liu A, Xin R, Zhang H, Dai L, Wu R, Wang X . An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1. Chin Med J (Engl). 2023; 135(22):2725-2729. PMC: 9944392. DOI: 10.1097/CM9.0000000000002494. View

15.

Chauveau M, Billaud E, Bonnet B, Merrien D, Hitoto H, Bouchez S . Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. J Antimicrob Chemother. 2019; 74(4):1021-1027. DOI: 10.1093/jac/dky547. View

16.

Delaney K, Wesolowski L, Owen S . The Evolution of HIV Testing Continues. Sex Transm Dis. 2017; 44(12):747-749. DOI: 10.1097/OLQ.0000000000000736. View

17.

. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-17):1-14. View

18.

Martin J, Escobar I, Rubio R, Sabugal G, Cascon J, Pulido F . Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV. HIV Clin Trials. 2001; 2(1):31-7. DOI: 10.1310/0Q8A-DFPR-6RV7-HX10. View

19.

Inciarte A, Leal L, Gonzalez E, Leon A, Lucero C, Mallolas J . Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother. 2017; 72(10):2857-2861. DOI: 10.1093/jac/dkx246. View

20.

Nhean S, Tseng A, Back D . The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. Curr Opin HIV AIDS. 2021; 16(6):292-302. DOI: 10.1097/COH.0000000000000701. View